Journal
NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-021-21085-8
Keywords
-
Categories
Funding
- National Key R& D Program of China [2020YFC0846600]
- Shandong Provincial Key R D Program [2020SFXGFY03]
- European Research Council (ERC) advanced grant ANGIOFAT [250021]
- Swedish Research Council
- Swedish Cancer Foundation
- Strategic Research Areas (SFO)-Stem Cell and Regeneration Medicine Foundation
- Karolinska Institutet
- Swedish Children's Cancer Foundation
- Karolinska Institutet Foundation
- Karolinska Institutet Distinguished Professor Award
- Torsten Soderbergs Foundation
- Maud and Birger Gustavsson Foundation
- Knut and Alice Wallenberg's Foundation
- Novo Nordisk Foundation-Advance grant
Ask authors/readers for more resources
In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO(2) ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.
On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate >= 30 times/min, oxygen saturation <= 93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O-2 ratio (PaO2/FiO(2)) >100mmHg and <= 300mmHg, and diffuse pneumonia confirmed by chest imaging. Followed up for 28 days. Among these, bevacizumab plus standard care markedly improves the PaO2/FiO(2) ratios at days 1 and 7. By day 28, 24 (92%) patients show improvement in oxygen-support status, 17 (65%) patients are discharged, and none show worsen oxygen-support status nor die. Significant reduction of lesion areas/ratios are shown in chest computed tomography (CT) or X-ray within 7 days. Of 14 patients with fever, body temperature normalizes within 72h in 13 (93%) patients. Relative to comparable controls, bevacizumab shows clinical efficacy by improving oxygenation and shortening oxygen-support duration. Our findings suggest bevacizumab plus standard care is highly beneficial for patients with severe Covid-19. Randomized controlled trial is warranted. In this single-arm clinical trial, the authors show that treatment of COVID-19 patients with bevacizumab, an anti-vascular endothelial growth factor drug, can improve PaO2/FiO(2) ratios and oxygen-support status. Relative to an external control group, bevacizumab shows clinical efficacy by improving oxygenation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available